tbuckley/cabot-search huggingface dataset:
Nucleic Acids From Subcellular Fractions of N-Nitrosodiethylamine-Induced Hepatoma in Mice
Authors: Jacob D. Shaposhnikov, Wolf N. Shalumovich, Oleg I. Kisselev, Vladimir S. Gaitskhoki, Kazymir M. Pozharisski
Journal: JNCI Journal of the National Cancer Institute (1976)

During eight successive isologous passages of hepatoma induced in male C3HA mice by N-nitrosodiethylamine, no common features of tumor progression were observed, although both the mitotic pattern and ploidy differed from generation to generation. These additional cytologic criteria allowed the biochemical examination of material least changed due to tumor progression. Tumor nDNA's were characterized by greater actinomycin D (AD)- and acridine orange (AO)-binding abilities than were normal nDNA's; this could have resulted from a higher proportion of double-stranded regions in tumor DNA. Isolated tumor deoxyribonucleoprotein had both lower template activity in an RNA polymerase system and fewer AD- and AO-binding sites, when compared with the activity and sites from normal mouse liver. RNA-DNA hybridization data with the above-mentioned findings showed that in hepatoma, part of the nuclear genome was repressed. Also, RNA "new classes" appeared and a certain proportion of nuclear genes controlling mitochondrial protein biosynthesis were derepressed in tumor mitochondria. The hybridization of mitochondrial RNA (mtRNA) and DNA revealed new classes of pulse-labeled RNA's in in vitro-incubated liver mitochondria that were absent from intact cell organelles; the hybridization properties of in vivo- and in vitro-formed hepatoma mtRNA's were similar. Competition and hybridization experiments demonstrated that in tumor mitochondria in vivo, some new classes of RNA existed. Hepatoma mitochondrial mRNA had a higher metabolic stability than did normal mRNA.
Massachusetts Medical Society
Authors: Charles G. Shedd, Urban Eversole, Joseph B. Stull, John S. Gale, Jack S. Parker, Charles G. Hayden, F. Woodward Lewis, Michael V. Mackenzie, Claude E. Welch
Journal: New England Journal of Medicine (1966)

COMMITTEE ON PHYSICIANS' PAYMENTS UNDER MEDICAREOn July 1, 1966, Blue Shield, as designated carrier, will begin to administer Part B of Medicare. Under this program Blue Shield will be responsible for determining reasonable charges for physicians' services.Patient beneficiaries of Part B of Medicare will be entitled to 80 per cent of reasonable charges after they have incurred charges amounting to $50 per calendar year. Some beneficiaries of Part B will also have a Blue Cross–Blue Shield Medicare Extension Plan (Medex), which will cover the $50 deductible and the 20 per cent coinsurance.It is estimated that more than . . .
Recombinant scinderin, an F-actin severing protein, increases calcium- induced release of serotonin from permeabilized platelets, an effect blocked by two scinderin-derived actin-binding peptides and phosphatidylinositol 4,5-bisphosphate
Authors: MG Marcu, L Zhang, K Nau-Staudt, JM Trifaro
Journal: Blood (1996)
Proteasome inhibitor associated thrombotic microangiopathy
Authors: Jennifer C. Yui, Jan Van Keer, Brendan M. Weiss, Adam J. Waxman, Matthew B. Palmer, Vivette D. D'Agati, Efstathios Kastritis, Meletios A. Dimopoulos, Ravi Vij, Dhruv Bansal, David Dingli, Samih H. Nasr, Nelson Leung
Journal: American Journal of Hematology (2016)

A variety of medications have been implicated in the causation of thrombotic microangiopathy (TMA). Recently, a few case reports have emerged of TMA attributed to the proteasome inhibitors (PI) bortezomib and carfilzomib in patients with multiple myeloma. The aim of this case series was to better characterize the role of PI in the etiology of drug-induced TMA. We describe eleven patients from six medical centers from around the world who developed TMA while being treated with PI. The median time between medication initiation and diagnosis of TMA was 21 days (range 5 days to 17 months). Median laboratory values at diagnosis included hemoglobin-7.5 g dL(-1) , platelet count-20 × 10(9) /L, LDH-698 U L(-1) , creatinine-3.12 mg dL(-1) . No patient had any other cause of TMA, including ADAMTS13 inhibition, other malignancy or use of any other medication previously associated with TMA. Nine patients had resolution of TMA without evidence of hemolysis after withdrawal of PI. Two patients had stabilization of laboratory values but persistent evidence of hemolysis despite medication withdrawal. One patient had recurrence of TMA with rechallenge of PI. There is a strong level of evidence that PI can cause DITMA. In evaluating patients with suspected TMA, PI use should be recognized as a potential etiology, and these medications should be discontinued promptly if thought to be the cause of TMA. Am. J. Hematol. 91:E348-E352, 2016. © 2016 Wiley Periodicals, Inc.
Measles outbreaks in London, United Kingdom - a preliminary report
Authors: R Heathcock, C Watts
Journal: Eurosurveillance (2008)

2007 saw the highest number of measles cases reported in England and Wales since current surveillance began in 1995, with 971 confirmed cases reported, compared with 740 reported in 2006 [1]. London was the region with the highest number of cases, and a large outbreak of measles in north-east London contributed to this high number of cases [2]. There were several outbreaks of measles elsewhere in Europe in 2007, and case have been reported this year in Switzerland [3], France [4] and Denmark [5].
Description and evaluation of the Iowa Depression Awareness, Recognition, and Treatment Program
Authors: M W O'Hara, L L Gorman, E J Wright
Journal: American Journal of Psychiatry (1996)

The National Institute of Mental Health developed the Depression Awareness, Recognition, and Treatment Program to provide up-to-date information and training to health, mental health, and social service professionals regarding the identification and treatment of depression. This study was undertaken to evaluate a series of these programs for professionals who provide services to rural residents in the Midwest.The 18 2-day training programs were attended by a total of 1,221 participants, physicians, psychologists, social workers, and nurses. Participants' knowledge regarding depression was assessed both before and after each program. Practice characteristics and perceived ability to assess and treat depression were assessed. Finally, 6-month follow-up evaluations of the usefulness of the training to the participants were undertaken.Following the programs, participants evidenced significant increases in levels of knowledge of depression and a high degree of satisfaction with most elements of the program. Six-month follow-up evaluations indicated a continued positive evaluation of the program.These outcomes suggest that the goals of the Depression Awareness, Recognition, and Treatment Program were met and provide support for the wider dissemination of these training programs.
Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model
Authors: Oh-Joon Kwon, Li Zhang, Jianghua Wang, Qingtai Su, Qin Feng, Xiang H.F. Zhang, Sendurai A. Mani, Robia Paulter, Chad J. Creighton, Michael M. Ittmann, Li Xin
Journal: Journal of Clinical Investigation (2016)

Although Notch signaling is deregulated in prostate cancer, the role of this pathway in disease development and progression is not fully understood. Here, we analyzed 2 human prostate cancer data sets and found that higher Notch signaling correlates with increased metastatic potential and worse disease survival rates. We used the Pten-null mouse prostate cancer model to investigate the function of Notch signaling in the initiation and progression of prostate cancer. Disruption of the transcription factor RBPJ in Pten-null mice revealed that endogenous canonical Notch signaling is not required for disease initiation and progression. However, augmentation of Notch activity in this model promoted both proliferation and apoptosis of prostate epithelial cells, which collectively reduced the primary tumor burden. The increase in cellular apoptosis was linked to DNA damage-induced p53 activation. Despite a reduced primary tumor burden, Notch activation in Pten-null mice promoted epithelial-mesenchymal transition and FOXC2-dependent tumor metastases but did not confer resistance to androgen deprivation. Notch activation also resulted in transformation of seminal vesicle epithelial cells in Pten-null mice. Our study highlights a multifaceted role for Notch signaling in distinct aspects of prostate cancer biology and supports Notch as a potential therapeutic target for metastatic prostate cancer.
Molecular basis of Sp alpha I/65 hereditary elliptocytosis in North Africa: insertion of a TTG triplet between codons 147 and 149 in the alpha-spectrin gene from five unrelated families
Authors: AF Roux, F Morle, D Guetarni, P Colonna, K Sahr, BG Forget, J Delaunay, J Godet
Journal: Blood (1989)
Dietary Fat and Colon Cancer1
Authors: Ernst L. Wynder, Bandaru S. Reddy
Journal: JNCI Journal of the National Cancer Institute (1975)

Dietary fat may be a risk factor in the absence of factors that are protective, such as use of high fibrous foods and fiber. The high-fat diet appears to enhance carcinogenesis through its elevation of agents that act as promoters of tumor development. This chapter describes research both epidemiologic and experimental, on the relation between dietary fat and large bowel cancer, including the use of animal models to determine if implicated factors can be modified experimentally. It explains various initiators and promoters involved in colon carcinogenesis. The chapter presents an evaluation of the mechanism whereby dietary fat modulates to high risk for the development of the important cancer. The effect of dietary fiber on fecal bile acids has been studied in many laboratories. Reddy studied the fecal bile acid excretion in healthy controls in Kuopio, a low-risk population for colon cancer development.
Paroxysmal Nocturnal Haemoglobinuria Clone In Aplastic Anaemia Patients At The Beginning Of Disease and In Remission
Authors: Zalina Fidarova, Elena Mikhailova, Svetlana Lugovskaia, Elena Naumova, Vera Troitskaia, Elena Ustinova, Margarita Pochtar, Kisilichina Daria, Irina Galtseva, Irina Shitareva, Larisa Kuzmina, Elena Parovichnikova, Valeriy Savchenko
Journal: Blood (2013)
The fortuitous diagnosis of <scp>B</scp>urkitt lymphoma in a patient with chronic myelomonocytic leukemia
Authors: Silvia Sale, Maurizio Fumi, Ylenia Pancione, Domenico Parente, Vincenzo Rocco, Barbara J. Bain
Journal: American Journal of Hematology (2016)

An 83-year-old woman had been under regular follow-up for 10 years with a diagnosis of chronic myelomonocytic leukemia (CMML) when a blood count showed that her hemoglobin concentration (Hb) had fallen by 20 g/l. There were no other unexpected findings on physical examination or in the blood count or film. Bone marrow aspiration was performed to investigate the fall in Hb. Aspirate films showed monocytosis and neutrophil dysplasia. However, unexpectedly, they also showed a population of medium-sized blast-like cells with strongly basophilic, heavily vacuolated cytoplasm, comprising a third of bone marrow cells (top left and right). Flow cytometric immunophenotyping showed expression of CD19, CD20, and CD79b with lambda light chain restriction. CD34 was negative. Staining for Ki-67 showed a very high proliferation fraction (bottom left). Myeloid blast cells expressing CD34, CD13, and CD33 were <1%. A diagnosis of Burkitt lymphoma was made, a very unexpected finding in an elderly woman with CMML with no cause for concern other than a fall in the Hb. Twenty days later Burkitt lymphoma cells appeared in the peripheral blood (bottom right).
Castration induced by cytotoxic chemotherapy.
Authors: H Brincker, H T Mouridsen, K W Andersen, C Rose, P Dombernowsky
Journal: Journal of Clinical Oncology (1989)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1989.7.5.679 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2651582 Castration induced by cytotoxic chemotherapy. H BrinckerxH BrinckerSearch for articles by this author , H T MouridsenxH T MouridsenSearch for articles by this author , K W AndersenxK W AndersenSearch for articles by this author , C RosexC RoseSearch for articles by this author , P DombernowskyxP DombernowskySearch for articles by this author https://doi.org/10.1200/JCO.1989.7.5.679 PDF "Castration induced by cytotoxic chemotherapy.." Journal of Clinical Oncology, 7(5), pp. 679–680© 1989 by American Society of Clinical Oncology
PTH-279 Medium term oncological outcomes of single incision laparoscopic surgery for rectal cancer
Authors: K Gash, M Bicsak, A Dixon
Journal: Gut (2015)

<h3>Introduction</h3> Conventional laparoscopic surgery for rectal cancer management is now widely accepted as a suitable alternative to open surgery; bestowing specific advantages, without causing detriment to oncological outcome. Evolving from this, single-incision laparoscopic surgery (SILS) has been successfully utilised for the removal of colonic tumours. However, the literature lacks data analysing the suitability of SILS for rectal cancer resection, particularly in terms of oncological outcome. We report medium term oncological outcomes from a prospective observational study of SILS for rectal cancer, including both high and low anterior resections. <h3>Method</h3> A prospective electronic database was collated of all patients undergoing SILS rectal cancer resection in our institution, between 2009 and 2014. In addition to patient, tumour and operative data, histo-pathological and medium term oncological outcomes were recorded. Kaplan Meier curves were used to analyse survival, performed using SPSS® Statistics version 21.0 for Windows ® (IBM, Armonk, New York, USA). <h3>Results</h3> Sixty-one patients underwent SILS for rectal cancer: high anterior resection (34); Total Mesorectal Excision (TME) (24) and TME with hand sewn colo-anal anastomosis (3). Median operative time was 105 min (37–280 mins) and 92% of cases were completed via SILS. Mean time to diet was 11 h and median length of stay was 2 days (1–8 days). Median number of lymph nodes harvested was 18 (6–44) and all were R0 resections. After a median follow-up of 46 months (16–64 months), 8 patients developed further disease (13.1%), of whom 5 had liver metastases (8.2%) and 3 developed widespread metastatic disease and local recurrence (4.9%). Three patients have died (4.9%), all of whom had metastases. The mean time to recurrent disease diagnosis was 7 months (2–17months) and post-operative survival of those who died was 29 months, 33 months and 53 months respectively. Kaplan Meier Survival Curves for disease free survival (including local recurrence, metastases and death) are shown in Figure 1. <h3>Conclusion</h3> Anterior resection and TME for rectal cancer can be safely performed by the SILS technique, with appropriate histo-pathological results and, crucially, good oncological outcomes. SILS rectal cancer surgery may confer additional advantages over conventional multiport surgery, such as reduced operating time and length of hospital stay. <h3>Disclosure of interest</h3> None Declared.
An imported case of canine rabies in Aquitaine: Investigation and management of the contacts at risk, August 2004-March 2005
Authors: V Servas, A Mailles, D Neau, C Castor, A Manetti, E Fouquet, J M Ragnaud, H Bourhy, M C Paty, N Melik, J Astoul, F Cliquet, M P Moiton, C François, M Coustillas, J- C Minet, P Parriaud, I Capek, L Filleul
Journal: Eurosurveillance (2005)

In August 2004, a case of rabies was diagnosed in a puppy that had been illegally imported from Morocco to Bordeaux (France). Because a great number of people and animals were thought to have come into contact with the puppy, extensive tracing measures were implemented, and an international alert was launched to trace and treat the contacts at risk. One hundred and eighty seven people received post-exposure treatment, eight of whom also received serovaccination, and 57 animals known to have been exposed to the puppy were tested. Six months after the death of the rabid animal, none of the people treated showed any signs of rabies, nor was any secondary animal case reported. The management of this crisis highlights the importance of the role of a rapid alert system at European level. Strict application of sanitary control regulations is essential for animals introduced into EU countries, and all necessary information must be made available to EU residents travelling to rabies enzootic areas.
FRI0056 Serum IL-10 and IP-10 Levels is an Important Predictor of Response to Tocilizumab in Bio-Naïve RA Patients
Authors: T. Kameda, H. Dobashi, M. Inoo, I. Onishi, N. Kurata, K. Susaki, R. Wakiya, H. Ozaki, S. Nakashima, H. Shimada, Y. Takeuchi, M. Izumikawa
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> The efficacy of biologics is different on respective RA patients. Therefore we have to select the best one among all biologics for each RA patient. On the other hand, there is few report about good predictive biomarker for the efficacy of biologics before administration<sup>1,2</sup>. Consequently, it is important that we identify the novel biomarker to predict the efficacy of these agents before the administration of biologics. In our facility, we investigated the serum cytokines of responder or poor responder RA patients treated with Tocilizumab (TCZ). Thirty-three serum cytokine levels before TCZ administration were measured using MILLIPLEX MAP Human Cytokine/Chemokine®. In these serum cytokines, we extracted IL-17, IL-6, IL-10, IL-13 and IP-10 as novel biomarker to predict the effectiveness of TCZ. <h3>Objectives</h3> We focused on serum cytokines such as IL-17, IL-6, IL-10, IL-13 and IP-10 in Bio-naïve RA patients treated with TCZ, and reveal characteristics of biomarkers to predict the efficacy of this biologics. <h3>Methods</h3> We enrolled 27 bio-naïve RA patients before TCZ administration. We measured these five serum cytokines using ELISA. We divided these 27 bio-naïve RA patients into clinical remission (CR; DAS28 ESR &lt;2.6) and non-CR (DAS28 ESR &gt;2.6) group at week 24, and compared these cytokines in two groups. <h3>Results</h3> Mean age was 57.6±15.9 years old and mean disease duration was 77.1±86.2 months. Disease activity of RA before TCZ administration was 4.48±0.87 and 5.01±1.26 with DAS28 ESR in CR (n=19) and non-CR (n=8), respectively. There was no difference in patient profile between two groups. In CR group, the serum IL-10 and IP-10 levels increased compared with non-CR group by ELISA, significantly (P&lt;0.05). There is no difference between two groups in the levels of IL-17, IL-6 and IL-13. <h3>Conclusions</h3> In our study, the serum levels of IL-10 and IP-10 before TCZ administration were different between CR and non-CR at week 24 with Bio-naïve RA patients. We suggest that serum IL-10 and IP-10 levels could predict the efficacy of TCZ on bio-naïve RA patients. <h3>References</h3> Gibbons LJ, Hyrich KL. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. BioDrugs. 2009; 23(2): 111-24. Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy. Arthritis Res Ther. 2011 Jul 30; 13 (4): R126. <h3>Disclosure of Interest</h3> None declared
AB0534 Podocytic Abnormalities in SLE – Parallel Mechanism Affecting Kidney
Authors: M. Vankalakunti, V.K.R. Rao, B. Dharmanand, R. Bhat, V. Guptha, S. Rani, L. Umesh, S. Nalloor, J. Kiran, M. Bipin, S. Rampure, K. Babu, R. Bonu, S. Ballal
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Renal involvement occurs in 40-70% of SLE patients. Biopsy is performed to look for the class of lupus nephritis. <h3>Objectives</h3> We describe clinicopathological and treatment outcomes of ten cases of SLE podocytic lesions. <h3>Methods</h3> A retrospective evaluation of 10,482 native renal biopsies referred to our institute during the period Jan 2010-Dec 2014 revealed 710 (6.8%) cases of lupus nephritis (LN). Distinct ten cases with biopsy proven LN with podocytic lesions formed the current case-series. Detailed clinical, lab investigations, renal biopsy, treatment &amp; follow-up information were obtained from medical records. <h3>Results</h3> All were females aged between 16-46 yrs and duration of illness was 1 week–8 years. Clinical findings included nephrotic syndrome with hypoalbuminemia in all (2 weeks-5 months duration), renal insufficiency in four and extra-renal flare of lupus in one. Urinalysis revealed ≥2+ proteinuria in all. Urine sediments were bland sediments in 6 cases &amp; active sediments in 2 cases. Proteinuria ranged between 3–24 gm/day. Renal histology showed isolated podocytopathies in seven cases [Focal Segmental Glomerulosclerosis (FSGS), tip variant (1); Minimal Change Nephrotic Syndrome (MCNS) with class-II LN (5); isolated collapsing FSGS (1)] and combination of proliferative lupus nephritis and podocytopathies in three cases [collapsing FSGS with class-III LN (1); collapsing FSGS with class-IV LN (1); &amp; collapsing FSGS with class-VI LN (1)]. EM study was available in 2 cases which revealed diffuse effacement of foot processes. Isolated podocytopathy was treated with steroids (1 mg/kg) and hydroxychloroquine. Complete clinical remission was achieved in 4/7 cases with isolated podocytopathy during 3-7 months period. Among the three cases with podocytopathy and renal insufficiency, one progressed to end stage kidney disease, two required cyclophosphamide and steroids. <h3>Conclusions</h3> Podocytic lesions in lupus, although generally present as nephrotic range proteinuria, it could also accentuate the damage caused by immune-mediated glomerular injury. In our cases, isolated podocytic lesions responded well to steroids and hydroxychloroquine, but those with associated renal dysfunction required aggressive treatment. Although biopsy is required to look for the class, our cases highlight the importance of recognizing podocytopathy as an alternative cause for nephrotic syndrome in lupus and raises the discussion of adding a sub-class to the ISN/ RPS system for guiding therapy and prognosis. <h3>Disclosure of Interest</h3> None declared